

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

## **LISTING OF CLAIMS:**

1-12. (Cancelled)

13. (Previously Presented) A method of treating a solid tumor, comprising administering an effective amount of camptothecin, or a camptothecin derivative, as a first agent, in combination with an effective amount of a topoisomerase II inhibitor as a second agent, wherein the agents are administered simultaneously, semi-simultaneously, or separately, and wherein said first and second agents provide a therapeutic synergy superior to each of the agents used alone at its optimum dose in the treatment of said solid tumor.

14. (Original) The method according to Claim 13, wherein the campotothecin derivative is CPT-11, and the topoisomerase II inhibitor is an anthracycline antibiotic.

15. (Original) The method according to Claim 14, wherein said antibiotic is doxorubicin.

16. (Original) The method according to Claim 14, wherein said antibiotic is daunorubicin.

17. (Original) The method according to Claim 13, wherein the campotothecin derivative is CPT-11, and the topoisomerase II inhibitor is an epipodophyllotoxin.

18. (Original) The method according to claim 17, wherein said epipodophyllotoxin is etoposide.
19. (Original) The method according to Claim 17, wherein said epipodophyllotoxin is teniposide.
20. (Original) The method according to any one of Claims 13-19, wherein the camptothecin derivative is administered orally.
21. (New) The method according to Claim 13, wherein the first agent is CPT-11.
22. (New) The method according to Claim 14, wherein the anthracycline antibiotic is daunorubicin, doxorubicin, annamycin, epirubicin, mitomycin, bleomycin, idamycin or cororubicin.
23. (New) The method according to Claim 13, wherein the solid tumor is a mammary adenocarcinoma.
24. (New) The method according to Claim 13, wherein the solid tumor is a pancreatic ductal adenocarcinoma.
25. (New) The method according to Claim 21, wherein the CPT-11 is administered orally or intravenously.

26. (New) The method according to Claim 13, wherein the second agent is administered intravenously.

27. (New) The method according to Claim 13, wherein the first agent is CPT-11 and is administered orally or intravenously and the second agent is administered intravenously.